Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GliomaAI-Astro23: Non-Invasive MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3) Using Artificial Intelligence

NCT07673666 is registered in ClinicalTrials.gov with Deep Learning Institute of Radiological Sciences as lead sponsor.

NCT NCT07673666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07673666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GliomaAI-Astro23: Non-Invasive MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3) Using Artificial Intelligence
Lead sponsor
Deep Learning Institute of Radiological Sciences
Phase
Observational
Overall status
Completed
Start date
March 14, 2017
Completion date
July 16, 2021
Enrollment
1,372 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, astrocytoma of brain, astrocytoma, grade ii, astrocytoma, idh-mutant, grade 2, astrocytoma, idh-mutant, grade 3, glioma, glioma (diagnosis)